- Home
- ICON vs MBIO Comparison
ICON vs MBIO Comparison
Compare ICON & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ICON | MBIO |
|---|---|---|
| Founded | 2023 | 2015 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 4.7M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | ICON | MBIO |
|---|---|---|
| Price | $0.66 | $1.15 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.50 | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 98.4K |
| Earning Date | 04-02-2026 | 11-07-2025 |
| Dividend Yield | ★ 1297.27% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,449,000.00 | N/A |
| Revenue This Year | $94.05 | N/A |
| Revenue Next Year | $18.81 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 96.44 | N/A |
| 52 Week Low | $0.69 | $0.89 |
| 52 Week High | $106.60 | $21.95 |
Technical Indicators
Market Signals| Indicator | ICON | MBIO |
|---|---|---|
| Relative Strength Index (RSI) | 23.16 | 40.41 |
| Support Level | $0.72 | $1.21 |
| Resistance Level | $0.83 | $1.31 |
| Average True Range (ATR) | 0.08 | 0.09 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 0.00 | 5.12 |
Price Performance
Historical ComparisonAbout ICON Icon Energy Corp.
Icon Energy Corp is a growth-oriented shipping company providing seaborne transportation services for dry bulk cargoes via its fleet of oceangoing vessels. The company generates its revenues by chartering its vessels to regional and international dry bulk operators, commodity traders and end users.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.